Skip to content

The Effect of Remifentanil on ED95 of Remimazolam for Loss of Consciousness in Adult Patients

The Effect of Remifentanil on ED95 of Remimazolam for Loss of Consciousness in Adult Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05434494
Enrollment
80
Registered
2022-06-28
Start date
2022-07-01
Completion date
2023-08-31
Last updated
2022-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Remimazolam

Brief summary

This study prospectively uses the biased coin technique to investigate the effect of concomitant administration of remifentanil on the 95% effective dose of intravenous remimazolam (Effective dose 95 \[ED95\]) required for loss of consciousness during anesthesia induction. .

Interventions

DRUGRemimazolam

Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method. If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19.

DRUGremifantanil

25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.

Sponsors

Ajou University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* The adult patients who are scheduled to surgery under general anesthesia

Exclusion criteria

* Severe obesity (BMI \> 30 kg/m2) * Allergy to remimazolam or remifentanil * Under conditions which make it difficult to respond to the investigator's verbal commends like hearing impairment, etc. * Patients with general conditions are more than ASA class III * Patients with brain disease (dementia, cerebral infarction, etc.)

Design outcomes

Primary

MeasureTime frameDescription
Remimazolam dose at which loss of consciousness occurs3 min after remimazolam injectionWhile slowly injecting the prescribed dose of remimazolam over 30 seconds, observe whether it responds to the investigator's oral commands and the disappearance of the eyelash reflex for 3 minutes after administering the drug. Success in inducing loss of consciousness during anesthesia is defined as the loss of both verbal command response and eyelash reflex within 3 minutes after infusion, otherwise it is considered a failure.

Secondary

MeasureTime frameDescription
Time to loss of consciousnesstime after injection of remimazolam to loss of conciousnessAfter injection of remimazolam, the investigator concludes the successful loss of consciousness (not respond to oral commands and the disappearance of the eyelash reflex); From remimazolam injection until loss of consciousness occurs

Contacts

Primary Contactji young yoo
anesyoo@aumc.ac.kr01056902104

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026